Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Infliximab, azathioprine, or combination therapy for Crohn's disease.
- J. F. Colombel, W. Sandborn, +10 authors P. Rutgeerts
- Medicine
- The New England journal of medicine
- 15 April 2010
BACKGROUND
The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown.
METHODS
In this randomized, double-blind trial, we… Expand
Infliximab for induction and maintenance therapy for ulcerative colitis.
- P. Rutgeerts, W. Sandborn, +11 authors J. F. Colombel
- Medicine
- The New England journal of medicine
- 8 December 2005
BACKGROUND
Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis.
METHODS
Two… Expand
Infliximab maintenance therapy for fistulizing Crohn's disease.
- B. Sands, F. Anderson, +15 authors S. V. van Deventer
- Medicine
- The New England journal of medicine
- 26 February 2004
BACKGROUND
Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab… Expand
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
- D. Rachmilewitz
- Medicine
- BMJ
- 14 January 1989
OBJECTIVE--To assess the safety and efficacy of a preparation of mesalazine (5-aminosalicylic acid) coated with a pH dependent resin (Eudragit L) as compared with sulphasalazine in patients with… Expand
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.
- D. Rachmilewitz, K. Katakura, +8 authors E. Raz
- Biology, Medicine
- Gastroenterology
- 1 February 2004
BACKGROUND & AIMS
We tested whether the attenuation of experimental colitis by live probiotic bacteria is due to their immunostimulatory DNA, whether toll-like receptor (TLR) signaling is required,… Expand
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
- P. Rutgeerts, B. Feagan, +8 authors S. Hanauer
- Medicine
- Gastroenterology
- 1 February 2004
BACKGROUND & AIMS
This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice.… Expand
A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998
- C. Gasche, J. Scholmerich, +8 authors L. Sutherland
- Medicine
- Inflammatory bowel diseases
- 1 February 2000
Summary: Crohn's disease is a heterogeneous entity. Previous attempts of classification have been based primarily on anatomic location and behavior of disease. However, no uniform definition of… Expand
Toll-like receptor 9-induced type I IFN protects mice from experimental colitis.
- K. Katakura, J. Lee, D. Rachmilewitz, G. Li, L. Eckmann, E. Raz
- Biology, Medicine
- The Journal of clinical investigation
- 1 March 2005
Experimental colitis is mediated by inflammatory or dysregulated immune responses to microbial factors of the gastrointestinal tract. In this study we observed that administration of Toll-like… Expand
Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease.
- D. Rachmilewitz, J. Stamler, D. Bachwich, F. Karmeli, Z. Ackerman, D. Podolsky
- Medicine
- Gut
- 1 May 1995
Recent studies have suggested that nitric oxide (NO.), the product of nitric oxide synthase in inflammatory cells, may play a part in tissue injury and inflammation through its oxidative metabolism.… Expand
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
- W. Sandborn, P. Rutgeerts, +12 authors Jean Frédéric Colombel
- Medicine
- Gastroenterology
- 1 October 2009
BACKGROUND & AIMS
The efficacy of infliximab for treating patients with ulcerative colitis has been established.
METHODS
The Active Ulcerative Colitis Trial (ACT)-1 and ACT-2 randomized,… Expand